title: Progressive diffuse meningioangiomatosis: Response to bevacizumab treatment.
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX. liorshlomit@yahoo.com.
authors.forename: Shlomit
authors.initials: S
authors.lastname: Yust-Katz
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX.
authors.forename: Gregory
authors.initials: G
authors.lastname: Fuller
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX.
authors.forename: Suzana
authors.initials: S
authors.lastname: Fichman-Horn
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX.
authors.forename: Natalia
authors.initials: N
authors.lastname: Michaeli
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX.
authors.forename: Edna
authors.initials: E
authors.lastname: Inbar
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX.
authors.forename: Judith
authors.initials: J
authors.lastname: Lukman
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX.
authors.forename: Dror
authors.initials: D
authors.lastname: Limon
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX.
authors.forename: Israel
authors.initials: I
authors.lastname: Steiner
authors.affiliation: From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX.
authors.forename: Tali
authors.initials: T
authors.lastname: Siegal
mesh_terms: D000368:Aged; D000798:Angiomatosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008578:Meninges / Q000473:pathology*
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000068258:Bevacizumab